Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma.

ABSTRACT: A population pharmacokinetic model was developed using data from healthy subjects and patients with moderate-to-severe asthma receiving intravenous or subcutaneous dupilumab doses. A total of nine phase I to phase III studies were pooled (202 healthy subjects and 1912 patients with asthma including 68 adolescents) in the model development. The best model was a two-compartment model with parallel linear and nonlinear Michaelis-Menten elimination with first order absorption. The PK parameter estimates were distribution volume of central compartment 2.76 L, linear elimination rate 0.0418 1/day, and subcutaneous bioavailability 60.9%. Pharmacokinetics (PK) properties of dupilumab in patients with asthma were determined to be comparable to those of healthy subjects and patients with atopic derm

SUBMITTER: Zhang L 

PROVIDER: S-EPMC8376131 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature